Virtual Morning Symposium –New Treatment Paradigm in RA: Focusing on A Novel JAK inhibitor
Saturday 24 October – 11:30am – 12:45pm

Check out the morning symposium!

 

Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. Gilead’s Inflammation R&D team is focused on improving therapeutic options for the treatment of multiple inflammatory conditions through a comprehensive clinical trial program evaluating novel agents with the goal of advancing patient care.